Gennao Bio is a genetic medicines company developing first‑in‑class targeted nucleic acid therapeutics using a proprietary gene monoclonal antibody (GMAB) platform licensed from Yale University. GMAB employs a novel, cell‑penetrating antibody to non‑covalently bind and deliver multiple classes of nucleic acid payloads to select cells as a non‑viral delivery system. The platform is differentiated by its ability to deliver multiple types of nucleic acids, enable repeat dosing, and use well‑established manufacturing processes. Gennao is initially focused on developing targeted, cell‑penetrating therapeutics for oncology and rare monogenic skeletal muscle diseases. The company closed a $40 million Series A in May 2021 to advance its GMAB platform and develop product candidates. Leadership changes announced with the financing include the appointment of Stephen Squinto, Ph.D., as CEO and chair.

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

May 2021